Special Issue "Hybrid Compounds, Multitarget Ligands, and Conjugate Derivatives as New Targeted Anticancer Agents"
Deadline for manuscript submissions: 31 December 2021.
Interests: medicinal chemistry; drug design; enzyme inhibitors; heme oxygenase-1 inhibitors; nitric oxide inhibitors; heme oxygenase-1 inducers; antitumor drugs; imidazole; receptor ligands; hybrid compounds
Special Issues, Collections and Topics in MDPI journals
Cancer is a multigenic disease characterized by dysregulated signaling pathways, molecular alterations, and cells' abnormal functions, cellular modifications that make cancer a highly complex medical condition to treat. Moreover, the clinical efficacy of certain anticancer mono-therapies can be mitigated by the development of drug resistance during the treatment. For these reasons, frequently, the combination of drug therapies is needed to obtain additive or synergistic effects as well as to overcome drug resistance. To this extend, the simultaneous modulation of multiple targets by using one molecule acting as a multitarget ligand or hybrid compound may represent a valuable option to avoid general issues associated with the co-administration of two or more agents.
This Special Issue aims to collect original research papers, short communications, and review articles on last advances in the development of hybrid compounds, multitarget ligands, and conjugate derivatives as new targeted anticancer agents. Contributions may cover multidisciplinary aspects of the design, synthesis, and pharmacological evaluation of novel polypharmacological agents with potential therapeutic innovation.
Prof. Dr. Loredana Salerno
Dr. Sebastiano Intagliata
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Hybrid compounds
- Multitarget Ligands
- Conjugate derivatives
- Anticancer agents
- Anticancer therapy
- Drug development
- Chemical synthesis
- Pharmacological evaluation
- Biological activity
- Drug resistance